US Parents Turn to Obesity Drugs for Children Amid Health Concerns

In the United States, a growing number of parents are opting for GLP-1 class drugs, such as Wegovy and Mounjaro, to treat their children's obesity. This decision stems from serious health concerns associated with excess weight in young individuals. For instance, Jenna Ceriani began GLP-1 treatment for her 10-year-old son, who weighed around 70 kg (154 lbs). His weight had previously led to his expulsion from a youth football league due to exceeding the 57 kg (125 lbs) limit.

Ceriani stated that the choice for medication was "for my son's health" and emphasized that the issue extends beyond mere weight. She expressed a desire for her son to avoid long-term health complications like diabetes and to achieve healthy growth. The trend highlights a difficult decision for parents balancing immediate health risks with the long-term implications of medicating children.

While the medical community generally advises lifestyle changes for childhood obesity, the increasing prevalence of severe cases and the availability of these new drugs are prompting some parents to seek pharmaceutical interventions. The debate continues regarding the safety and efficacy of using these powerful medications on children and adolescents whose bodies are still developing. The long-term effects and ethical considerations remain central to the ongoing discussion.

“

This is not just about weight.